 |
News |
|
Biotest Pharmaceuticals Corporation provides donation to the Immune Deficiency Foundation February 9, 2009 - Earlier this year Biotest provided a significant donation to the Immune Deficiency Foundation (IDF). Marcia Boyle, President and Founder of IDF, accepted the donation at Biotest Pharmaceuticals Corporation (BPC) Semi-Annual Employee Meeting where she made an informative presentation on Immune Deficiency. BPC’s donation will provide support to the Immune Deficiency Foundation’s (IDF) 2009 National Conference. Specifically, this funding will provide an educational opportunity for immunologists and medical professionals involved in the treatment of primary immunodeficiency disease. Also, additional funding has been provided for scholarships to assist some individuals who wish to attend the conference. BPC continues with its development of an Intravenous Immune Globulin and supports IDF’s long-term dedication to the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases. In addition, BPC is excited to announce its participation in the IDF Blue Jeans for Healthy Genes program which raises awareness of primary immunodeficiency diseases, while raising funds for further research and patient programs.
About Biotest Pharmaceuticals Corporation Biotest Pharmaceuticals researches and manufactures biotherapeutic products with a specialization in immunology and liver transplant therapy. Biotest Pharmaceuticals was formed in 2007 as part of the acquisition of Nabi Biopharmaceuticals’ Biologics business unit which includes its plasmapheresis centers across the United States by Biotest AG. The company employs more than 600 people in the US. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins therapies and diagnostics that employs approximately 1,950 people worldwide. To learn more about Biotest Pharmaceuticals and how we help make a difference in the lives of patients and the healthcare community, please visit us at www.biotestpharma.com. About Biotest AG Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic
and diagnostic products and has specialised in the areas of application of immunology and haematology. In its
Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based
on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the
Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and cancer of plasma cells. The products of the Microbiological Monitoring
segment are primarily used in hygiene monitoring, while those of Medical Diagnostics are used, for example, in
blood transfusions and transplants. Biotest has more than 1,950 employees worldwide. The shares of Biotest AG
are listed in the SDAX on the Frankfurt stock exchange. Contacts: Biotest Pharmaceuticals Corporation |
